We encountered two patients with uncommon neurological manifestations after allogeneic bone marrow transplantation (BMT), which occurred with rapid elevation of the leukocyte count at engraftment. Both patients then developed severe acute graft-versus-host disease (GVHD). To investigate the pathogenesis, we measured the levels of soluble P-selectin, von Willebrand factor (vWF) and thrombomodulin (TM), which reflect endothelial damage. The P-selectin, vWF and TM levels in the patients with (n = 2) and without (n = 5) neurotoxicity were, respectively, 168.5 ؎ 52.5 ng/ml vs 27.7 ؎ 3.9 ng/ml, 6.7 ؎ 0.15 FU/ml vs 3.42 ؎ 0.41 FU/ml and 459 ؎ 37% vs 189.4 ؎ 32.4% (mean ؎ s.d.). All three parameters were much higher in the patients with neurological complications. These results suggest that neurotoxicity after BMT may be related to endothelial damage. Keywords: BMT; P-selectin; thrombomodulin; von Willebrand factor; neurotoxicity Neurological complications are a frequent and important cause of morbidity and mortality after allogeneic BMT and several underlying mechanisms have been proposed for such complications. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] We encountered two BMT patients with neurological complications not previously described. We hypothesized that the neurotoxicity was related to endothelial damage, and investigated the levels of soluble P-selectin TM and vWF.
. Median age at time of transplantation was 27 years (range 25-37 years), and they included five men and two women. The underlying diseases were acute lymphoblastic leukemia (ALL) in three cases, chronic myelogenous leukemia (CML) in three cases, and acute myelogenous leukemia (AML) in one case.
Conditioning regimens
All patients with high-risk disease received total body irradiation with a regimen of 300 cGy daily over 4 days (to a total of 1200 cGy) from day Ϫ9 to day Ϫ6. Subsequently, oral busulfan (BU) was given at 1 mg/kg every 6 h for a total of 8 doses on days Ϫ4 and Ϫ3, while cyclophosphamide (CY) was given at 30 mg/kg on days Ϫ2 and Ϫ1.
GVHD prophylaxis
Four patients received pharmacological prophylaxis against GVHD with cyclosporin A (CsA), methylprednisolone (m-PSL) and methotrexate (MTX), according to Chao's protocol. 20 Two patients received FK506 instead of CsA, one patient received antithymocyte globulin (ATG) in addition to Chao's protocol, and one patient received ATG instead of CsA.
Investigations P-selectin: P-selectin is a 140-kDa protein found in the ␣-granules of platelets and the Weibel-Palade bodies of endothelial cells. On activation, it is expressed on the cell surface and secreted into the plasma. 21 An increase of the plasma P-selectin concentration may therefore indicate in vivo activation/damage of platelets and endothelial cells, 22 and elevated P-selectin levels in severe thrombocytopenia are thought to be due to vascular endothelial damage rather than platelet hyperfunction. 23 von Willebrand factor (vWF): vWF is found in the Weibel-Palade bodies and in megakaryocytes, and is also a component of platelet ␣-granules. 24 It is generally believed that the majority, if not all, of vWF in the plasma is derived from endothelial cells, and an increase of vWF is thought to be a specific marker of endothelial damage or activation. 25, 26 810 all-match ALL = acute lymphoblastic leukemia; 1 CR = first complete remission; BU = busulfan; CY = cyclophosphamide; TBI = total body irradiation; CsA = cyclosporin A; m-PSL = methylpredonisolone; MTX = methotrexate; AML = acute myelogenous leukemia; 2 CR = second complete remission; ATG = antithymocyte globulin; CML = chronic myelogenous leukemia; 1 CP = first chronic phase; AP = accelerated phase.
Thrombomodulin (TM):
TM is the thrombin receptor on the surface of endothelial cells in arteries, veins, capillaries and lymphatics, as well as on placental syncytiotrophoblast cells and platelets. It acts as a cofactor for thrombincatalysed activation of protein C, an anticoagulant protease zymogen. [27] [28] [29] An increase of TM may also result from endothelial damage.
Blood samples were obtained from the subjects on preconditioning day 0, once during the aplastic phase, when leukocytes were increasing with engraftment, on day 21, and on the occurrence of neurological complications. Blood was mixed with a one-tenth volume of 3.8% sodium citrate and then centrifuged at 1500 g at 4°C for 10 min. The supernatant was stored at Ϫ80°C until assay of P-selectin, vWF and TM using commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kits.
Patient 1 (Figure 1)
Confusion and disorientation occurred on day 13, when the leukocyte count was increasing rapidly with engraftment. His consciousness became clear again within 2 days, but he had no recollection of events during the period of disorientation. Computerized tomography (CT) scans of the head and analysis of cerebrospinal fluid (CSF) revealed no abnormalities.
Patient 2 (Figure 2)
An altered mental status and generalized seizures developed on day 12 when the leukocyte count was rapidly rising and engraftment was confirmed. Although his consciousness normalized, seizures were persistent and anticonvulsants were ineffective. He eventually required barbiturate therapy under controlled ventilation, and became seizure-free next day. Brain CT scans were normal, as was CSF analysis. After neurotoxicity had continued for a few days, the patient recovered without conscious sequelae, and had no recollection of events during the period of neurotoxicity.
Both patients received m-PSL, MTX and CsA for acute GVHD prophylaxis. The blood level of CsA was in the therapeutic range (Figures 1 and 2) , and marked elevation of LDH, fragmentation of peripheral red blood cells, or other sign of hemolysis were not observed at the time of neurotoxicity. Severe acute GVHD (grade IV in patient 1 and grade III in patient 2) developed from several days to a few weeks after recovery from neurotoxicity. Unfortunately both patients died of sepsis (day 141, patient 1; day 25, patient 2) while on immunosuppressive therapy for severe GVHD.
Results

P-selectin
The plasma P-selectin level was 78.9 Ϯ 66.6 ng/ml (mean Ϯ s.d.) in healthy subjects. 23 The level during the aplastic phase ranged from 14 to 37 ng/ml (mean Ϯ s.d.; 27.7 Ϯ 3.9 ng/ml) in the BMT patients. In the five patients without neurotoxicity, the P-selectin level ranged from 22 to 53 ng/ml (mean Ϯ s.d.; 40 Ϯ 5.3 ng/ml), until recovery of the platelet count, while patients 1 and 2 showed very high 
Thrombomodulin (TM)
The normal TM level was less than 4.5 FU/ml. TM was measured on the occurrence of neurotoxicity in patients 1 and 2 (on day 12 and day 13, respectively), while in the patients without neurotoxicity it was measured on day 12 or 13. The TM level was 6.8 and 6.5 FU/ml (mean Ϯ s.d.; 6.7 Ϯ 0.15 FU/ml) in patient 1 and patient 2, respectively, 
Discussion
We encountered two patients with CNS manifestations at time of marked elevation in the leukocyte count after BMT. Both patients had neurotoxicity at about the same time after BMT, recovered without obvious sequela, developed severe acute GVHD after neurological recovery, and died of sepsis. Neurological complications are a frequent and important cause of morbidity and mortality after allogeneic BMT. CsA, 1-10 MTX, 11-13 TBI, 11-13 corticosteroids, 5, 15 infection, 1,13,14 capillary leak syndrome (CLS), 2,16,17 thrombotic microangiopathy (TMA), 15 GVHD 1,15 and cytokines such as tumor necrosis factor alpha (TNF-␣), 18, 19 interferon gamma (IFN-␥) 15, 19 and IL-2 17, 18 have been proposed as mediators in such complications, but their pathogenesis is still controversial.
In this study, we evaluated previously described factors in our seven patients with and without neurological complications, but found no differences between treatment in the two groups. All patients were prepared with BU, CY and TBI as conditioning regimen, and most of them received CsA, m-PSL, and MTX for GVHD prophylaxis, so not all patients undergoing high-dose therapy show evidence of such complications. The two patients with neurotoxicity had neither CNS infection nor acute GVHD before the onset of symptoms. There was no evidence of TMA (such as fragmentation of red cells, marked elevation of LDH and other signs of hemolysis) and no features of CLS (excessive weight gain, ascites and edema). To investigate the pathogenesis, we determined the levels of P-selectin, vWF and TM before and after BMT. P-selectin may increase due to release from endothelial cells, platelets, and/or megakaryocytes, but the majority of P-selectin should be derived from endothelial cells during the aplastic phase after BMT. The P-selectin level was much higher in the patients with CNS complications than in those without complications, suggesting a relationship between neurotoxicity and endothelial damage. Such a relationship was strongly supported by the associated high levels of TM and vWF. Since TM is widely distributed in the systemic endothelium, except in brain vessels, endothelial damage apparently occurred not only in the brain but also throughout the body. 28 The two patients had characteristics not previously described, in that their neurotoxicity occurred earlier and coincided with rapid elevation of the leukocyte count. They both had fever with normal CSF during the aplastic phase, and developed severe acute GVHD from several days to a few weeks after recovery from neurotoxicity. Recently, several cases of cerebral infarction have been reported at the time of a rapid increase of leukocytes in patients with or without BMT. Conti et al 30 reported that arterial thrombosis in a patient receiving granulocyte colony-stimulating factor (G-CSF) was related to leukocytosis induced by this factor. 30 Shimoda et al 31 reported that the G-CSF receptor exists on platelets, and that G-CSF induces a hypercoagulable state by stimulating adenosine diphosphate. In our patients, conditioning for BMT may have caused initial endothelial damage that was aggravated by infection during the aplastic phase, resulting in a priming state. Severe injury could then be mediated by G-CSF and/or other cytokines during the phase of rapid leukocyte recovery. Systemic endothelial injury may result in damage to the colon, skin, liver and biliary tract as well as the brain, thus causing severe acute GVHD.
In summary, we present two patients with neurotoxicity at the time of elevation of the leukocyte count with engraftment after BMT. This neurotoxicity apppears to be related to endothelial damage because the patients both had high levels of P-selectin, TM and vWF. Such endothelial damage may be produced by various cytokines released from leukocytes stimulated by G-CSF and infection rather than by chemotherapy and radiotherapy related to BMT. It is difficult to draw valid conclusions from this study and a larger prospective study would be needed to test the hypothesis.
